Technology News and Research

RSS

PURE Bioscience qualifies for Russell 3000, Russell 2000 Indexes

PURE Bioscience today announced that it has been added to the Russell 3000® and Russell 2000® Indexes, which measure the performance of the largest U.S. companies based on total market capitalization. The Russell 2000 is the smaller 2,000 companies within the larger index. The annual reconstitution of the Russell Indexes occurred on Friday, June 25th.

28 Jun 2010

MagForce's Nano-Cancer therapy receives European regulatory approval

Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.

28 Jun 2010

Bayonne Medical Center implements Picis ED PulseCheck ahead of schedule

Picis announced today that Bayonne Medical Center, Bayonne, NJ, has successfully deployed Picis ED PulseCheck™, part of the CareSuite® family of high-acuity solutions, two months ahead of schedule. This aggressive implementation is aimed at helping clinicians in the emergency department (ED) better manage information and the process of treating over 28,000 ED patients annually.

28 Jun 2010

Arteriocyte honored as Venture of Year Award Finalist

Arteriocyte, Inc., was honored Friday by the Ohio Venture Association as a Venture of Year Award Finalist. Founded in 2004 to develop proprietary stem cell and tissue engineering based therapies, Arteriocyte focuses on developing commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage) for delivery to injured tissues in order to speed repair and improve function.

28 Jun 2010

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.

28 Jun 2010

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

ULURU Inc. announced today that Strakan International Limited and ULURU have divested their respective interest in Zindaclin® to a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Zindaclin® is a product for the treatment of acne which is outside the strategic focus of ULURU. This product was included in the technology package ULURU acquired when it was formed in 2005.

28 Jun 2010

FUJINON restructured into two subsidiaries

FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.

28 Jun 2010

Instant processing of insurance claims possible during doctor visit

The New York Times has a consumer health column on programs that would process a patient's insurance claim: "Here's how it could work: A claim is generated and submitted electronically before you finish tying your shoes. By the time you reach the checkout desk, your doctor has received a payment commitment from your insurance company, just as Visa and MasterCard provide to a merchant after a customer swipes a card. It's not fantasy.

28 Jun 2010

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed's anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.

28 Jun 2010

Fate Therapeutics recognized with Red Herring's North America 100 award

Fate Therapeutics, Inc. announced today that the Company received Red Herring's North America 100 award, a prestigious list honoring the year's most promising private and innovative companies from the North American business region. The nominees were evaluated by the Red Herring editorial team on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy and integration into their respective industries.

28 Jun 2010

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.

28 Jun 2010

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Masimo, the inventor of Masimo Rainbow Pulse CO-Oximetry™, Masimo Rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced FDA 510(k) clearance for the Pronto-7™—a new handheld device designed for quick and easy noninvasive hemoglobin (SpHb®) spot-check testing, along with SpO2, pulse rate, and perfusion index, in virtually any environment.

28 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.

28 Jun 2010

Scientists use PGS method to analyse chromosomal status of eggs

The efficacy of preimplantation genetic screening has been one of the most hotly disputed subjects in assisted reproduction over the past few years. The European Society of Human Reproduction and Embryology PGS Task Force has now shown, in its groundbreaking proof of principle study, that screening of polar bodies (small cells that are the by-product of egg development), is a reliable method to analyse the chromosomal status of an egg.

28 Jun 2010

New guides available to help hospital planners protect patients, health care workers

Two new guides are now available to help hospital planners and administrators make important decisions about how to protect patients and health care workers and assess the physical components of a hospital when a natural or manmade disaster, terrorist attack, or other catastrophic event threatens the soundness of a facility. Published by HHS' Agency for Healthcare Research and Quality, the guides examine how hospital personnel have coped under emergency situations in the past to better understand what factors should be considered when making evacuation, shelter-in-place, and reoccupation decisions.

28 Jun 2010

Quick-Med Technologies announces application for EPA registration of Stay Fresh technology

Quick-Med Technologies, Inc., a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, today announced its application for U.S. Environmental Protection Agency registration of the Company's proprietary Stay Fresh antimicrobial textiles technology.

28 Jun 2010

CMMC installs Toshiba's Vantage Titan MR system to accommodate bariatric patients

Obesity is a growing trend in the United States, requiring hospitals to provide medical imaging technology designed to accommodate bariatric patients without compromising diagnostic confidence or patient comfort. To accomplish this goal, Central Mississippi Medical Center in Jackson, Miss., a bariatric center of excellence, recently installed Toshiba America Medical Systems, Inc.'s Vantage Titan MR system.

28 Jun 2010

SurgiSteer laparoscopic instruments released in the US

Steerable Technologix LLC announces the US release of its SurgiSteer laparoscopic instruments. Developed from licensed technology from OrthoDynamix LLC, the SurgiSteer product line will exploit single port laparoscopic surgery with its steerable 5mm instrumentation. The Lap Grasper, Maryland Dissector and Endo Scissors, available in both free and ratchet handle configurations are simplistic in use versus competitive devices.

28 Jun 2010

Overweight women undertaking ART at increased risk of miscarriage

Being overweight leads to a greater risk of miscarriage for patients undergoing assisted reproductive technology (ART), the 26th annual conference of the European Society of Human Reproduction and Embryology heard today (Monday). Dr. Vivian Rittenberg, a Clinical Fellow in the Assisted Conception Unit, Guy's and St. Thomas' Hospital NHS Foundation Trust, London, UK, said that her research provided additional evidence to show that increased body mass index (BMI) was independently associated with a higher miscarriage rate after IVF or ICSI treatment.

28 Jun 2010

Technology News and Research

PURE Bioscience qualifies for Russell 3000, Russell 2000 Indexes

MagForce's Nano-Cancer therapy receives European regulatory approval

Bayonne Medical Center implements Picis ED PulseCheck ahead of schedule

Arteriocyte honored as Venture of Year Award Finalist

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

FUJINON restructured into two subsidiaries

Instant processing of insurance claims possible during doctor visit

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Fate Therapeutics recognized with Red Herring's North America 100 award

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

Scientists use PGS method to analyse chromosomal status of eggs

New guides available to help hospital planners protect patients, health care workers

Quick-Med Technologies announces application for EPA registration of Stay Fresh technology

CMMC installs Toshiba's Vantage Titan MR system to accommodate bariatric patients

SurgiSteer laparoscopic instruments released in the US

Overweight women undertaking ART at increased risk of miscarriage

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News